BINOSTO Drug Patent Profile
✉ Email this page to a colleague
When do Binosto patents expire, and what generic alternatives are available?
Binosto is a drug marketed by Radius and is included in one NDA. There is one patent protecting this drug.
This drug has twenty patent family members in sixteen countries.
The generic ingredient in BINOSTO is alendronate sodium. There are twenty-five drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Binosto
A generic version of BINOSTO was approved as alendronate sodium by APOTEX on August 4th, 2008.
Summary for BINOSTO
International Patents: | 20 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 2 |
Patent Applications: | 82 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BINOSTO |
What excipients (inactive ingredients) are in BINOSTO? | BINOSTO excipients list |
DailyMed Link: | BINOSTO at DailyMed |
Recent Clinical Trials for BINOSTO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
EffRx Pharmaceuticals | Phase 2 |
Amgen | Phase 2 |
University Hospital, Ghent | Phase 2 |
Pharmacology for BINOSTO
Drug Class | Bisphosphonate |
US Patents and Regulatory Information for BINOSTO
BINOSTO is protected by one US patents.
Patents protecting BINOSTO
Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Radius | BINOSTO | alendronate sodium | TABLET, EFFERVESCENT;ORAL | 202344-001 | Mar 12, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BINOSTO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Radius | BINOSTO | alendronate sodium | TABLET, EFFERVESCENT;ORAL | 202344-001 | Mar 12, 2012 | ⤷ Try a Trial | ⤷ Try a Trial |
Radius | BINOSTO | alendronate sodium | TABLET, EFFERVESCENT;ORAL | 202344-001 | Mar 12, 2012 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BINOSTO
See the table below for patents covering BINOSTO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 102011505 | ⤷ Try a Trial | |
Spain | 2448501 | ⤷ Try a Trial | |
World Intellectual Property Organization (WIPO) | 2012078528 | ⤷ Try a Trial | |
China | 103140220 | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics | ⤷ Try a Trial |
Canada | 2495886 | COMPOSITIONS EFFERVESCENTES CONTENANT DES BISPHOSPHONATES ETMETHODES CONNEXES (EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO) | ⤷ Try a Trial |
Israel | 224367 | תכשירי ביספוספונט יציבים תוססים עם תכונות מסיסות מהירה (Stable effervescent bisphosphonate formulations with rapid solubilization characteristics) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BINOSTO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1175904 | 2007C/048 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |